An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

A new study suggests Paxlovid may not reduce the risk of covid-19 hospitalizations and all-cause deaths in vaccinated adults ...

That’s very different from the results that Paxlovid’s maker, Pfizer, first reported in 2022. In that study, Pfizer found that the drug reduced hospitalizations and deaths from COVID-19 by 89% ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Representative Julie Johnson (D-Texas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 ...

“I think that needs to be part of the conversation.” A spokesperson for Pfizer, which makes Paxlovid, said the company stands ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

National rates of uterine rupture in trial of labor after cesarean increased from 0.20% in 2010 to 0.37% in 2022, with an ...

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

Paxlovid - Pfizer’s combination of nirmatrelvir and ritonavir - has been found to reduce symptoms, hospitalizations and deaths in unvaccinated, at-risk patients. However, a Pfizer trial ...